Lapuleucel-T, an investigational active cellular immunotherapy ACTIVE CELLULAR IMMUNOTHERAPY (ACI)An approach that uses live human cells to re-engage the patient's own immune system. The goal of active cellular immunotherapy (ACI) is to turn the immune system "back on" to elicit a specific long-lasting response against cancer.Close (ACI) has completed two Phase 1 Phase 1 Clinical TrialThe first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, Phase 1 trials usually include only a small number of patients who have not been helped by other treatments.Closeclinical trials for the potential treatment of patients with breast, ovarian and colorectal solid tumors expressing HER2/neu. Lapuleucel-T targets the HER2/neu antigen AntigenA substance that causes the body's immune system to react. This reaction often involves production of antibodies. For example, the immune system's response to antigens that are part of bacteria and viruses helps people resist infections. Cancer cells have certain antigens that can be found by laboratory tests. They are important in cancer diagnosis and in watching response to treatment. Other cancer cell antigens play a role in immune reactions that may help the body's resistance against cancer. Closeand utilizes the same proprietary antigen-engineering technology as sipuleucel-T, which is in late-stage clinical development. We are evaluating future development plans for lapuleucel-T.
Print page
Email page